

Disclosure Purpose: 22-01933

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Efficacy of Antiviral Agents Against the SARS-CoV-2 Omicron BA.2 Variant
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01933

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Efficacy of Antiviral Agents Against the SARS-CoV-2 Omicron BA.2 Variant
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-01933

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Ministry of Health, Labour and Welfare	Grant / Contract	Self
<i>Recipient Name:</i> Hideki Hasegawa <i>Grant / Contract Description:</i> 20HA2007 <i>Additional Information:</i>		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Efficacy of Antibodies and Antivirals Against a SARS-CoV-2 Omicron Variant.
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01933

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron BA.2 Variant
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-01933

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Efficacy of Antibodies and Antivirals Against a SARS-CoV-2 Omicron Variant
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01933

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Efficacy of Antiviral Agents Against the SARS-CoV-2 Omicron BA.2 Variant
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01933

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Daiichi Sankyo Company LTD	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> Development of influenza vaccines <i>Additional Information:</i>		
fujirebio	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
Japan Agency for Medical Research and Development	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> JP20nk0101632 <i>Additional Information:</i>		
Japan Agency for Medical Research and Development	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> JP21fk0108615 <i>Additional Information:</i>		
Japan Agency for Medical Research and Development	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> JP21fk0108104 <i>Additional Information:</i>		
Japan Agency for Medical Research and Development	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> JP20fk0108412 <i>Additional Information:</i>		
Japan Agency for Medical Research and Development	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> JP21wm0125002 <i>Additional Information:</i>		
KM Biologics	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> Development of novel influenza vaccines <i>Additional Information:</i>		
Kyoritsu Seiyaku	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> Development of adjuvants <i>Additional Information:</i>		
Ministry of Health, Labour and Welfare	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> 20HA2007 <i>Additional Information:</i>		
Otsuka Pharmaceutical Co., Ltd.	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> Evaluation of enteric bacteria <i>Additional Information:</i>		
Shinya Corporation	Grant / Contract	Self

<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> Development of vaccine device <i>Additional Information:</i>	<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research
shinya corporation	Grant / Contract Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> <i>Additional Information:</i>	<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research
Shionogi	Grant / Contract Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> Evaluation of influenza drugs <i>Additional Information:</i>	<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research
Tauns Laboratories	Grant / Contract Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> Development of influenza diagnostic kits <i>Additional Information:</i>	<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research
Toyama Chemical	Grant / Contract Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> Evaluation of influenza drugs <i>Additional Information:</i>	<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research
US NIH	Grant / Contract Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> 75N93021C00014 <i>Additional Information:</i>	<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research
US NIH	Grant / Contract Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> HHSN272201400008C <i>Additional Information:</i>	<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research

Intellectual Property

Type	Is Licensed	Interest Held By						
Patent - Influenza reverse genetics	Yes	Self						
<i>Description:</i> Influenza reverse genetics <i>Patent Status:</i> Issued <i>Filing Jurisdiction:</i> <i>Licensees:</i>		<i>Patent Number:</i> US 20160137987 A1 <i>Patent Holder:</i> <i>Additional Information:</i>						
<table border="1"> <thead> <tr> <th>Licensee</th> <th>Title</th> <th>Date</th> </tr> </thead> <tbody> <tr> <td>MedImmune, LLC</td> <td></td> <td></td> </tr> </tbody> </table>	Licensee	Title	Date	MedImmune, LLC				
Licensee	Title	Date						
MedImmune, LLC								

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Efficacy of antibodies and antivirals against the SARS-CoV-2 Omicron BA.2 variant
- Are you the corresponding author?
Yes.
 - Please list the other authors' names here.
Emi Takashita, Noriko Kinoshita, Seiya Yamayoshi, Yuko Sakai-Tagawa, Seiichiro Fujisaki, Mutsumi Ito, Kiyoko Iwatsuki-Horimoto, Peter Halfmann, Shinji Watanabe, Kenji Maeda, Masaki Imai, Hiroaki Mitsuya, Norio Ohmagari, Makoto Takeda, Hideki Hasegawa, Yoshihiro Kawaoka

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01933

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Efficacy of Antiviral Agents Against the SARS-CoV-2 Omicron BA.2 Variant
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01933

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Efficacy of Antibodies and Antivirals Against a SARS-CoV-2 Omicron Variant
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-01933

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Efficacy of Antibodies and Antivirals Against a SARS-CoV-2 Omicron Variant
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-01933

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Efficacy of Antiviral Agents Against the SARS-CoV-2 Omicron BA.2 Variant
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-01933

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. What is the manuscript title?**
Efficacy of Antibodies and Antivirals Against a SARS-CoV-2 Omicron Variant
- 3. Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-01933

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Efficacy of Antiviral Agents Against the SARS-CoV-2 Omicron BA.2 Variant
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-01933

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Efficacy of Antibodies and Antivirals Against a SARS-CoV-2 Omicron Variant
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01933

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Japan Agency for Medical Research and Development	Grant / Contract	Self
<i>Recipient Name:</i> Shinji Watanabe <i>Grant / Contract Description:</i> a Research Program on Emerging and Re-emerging Infectious Disease (#JP21fk0108104)		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i> JP21fk0108104

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Efficacy of antiviral agents against the SARS-CoV-2 Omicron BA.2 variant
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01933

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron BA.2 Variant
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

